Clinical trial
The NUVASCULAR HARBOR Occlusion Device EU Study
NCT07900464 is registered in ClinicalTrials.gov with Nuvascular Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The NUVASCULAR HARBOR Occlusion Device EU Study
- Lead sponsor
- Nuvascular Inc
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- October 26, 2026
- Completion date
- December 18, 2028
- Enrollment
- 30 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
intracranial arterial aneurysm
Arms
As registered; 1 arm.
-
HARBOR Occlusion Device
Participants with eligible intracranial aneurysms will receive endovascular treatment with the HARBOR Occlusion Device. The device is delivered through a microcatheter and implanted in the target aneurysm. Participants will undergo protocol-specified clinical, neurological, and imaging assessments through the 1-year follow-up visit.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Complete Aneurysm Occlusion Without Retreatment, Recurrent Subarachnoid Hemorrhage, or Significant Parent Artery Stenosis.
Proportion of participants with complete aneurysm occlusion and no retreatment, recurrent subarachnoid hemorrhage, or significant parent artery stenosis (\>50%) at 1 year after treatment. Participants must meet all criteria to be counted as an effectiveness success.
-
Proportion of Participants with Nonaccidental Death Cause or Major Stroke
Proportion of participants with death from any nonaccidental cause or major stroke within 30 days after treatment, or major ipsilateral stroke or death due to a neurological cause from day 31 through 1 year after treatment. Major stroke is defined as an ischemic or hemorrhagic stroke resulting in an increase of at least 4 points on the NIH Stroke Scale.
Lead sponsor's other trials
Nuvascular Inc, most recent start first.